Bundesministerium für Wirtschaft und Energie ZF4070803BA9: Entwicklung eines Verfahrens zur Bereitstellung EKG-äquivalenter Parameter, wie zum Beispiel des QT-Intervalls, mittels Puls-Plethysmografie. 05/2020-04/2023.
Sartorius A. BMBF - Bundesministerium für Bildung und Forschung 01EW2020B: NeuroMarKet WP2: Validation of the magnetic imaging-based markers, i.e. glutamatergic metabolite concentrations in pgACC and reduced RSFC within default mode network (DMN) in TRD patients and CUMS rats responding to ketamine’s antidepressant effec. 04/2020-03/2023.
Our previous work suggested the amount of RSFC changes within DMN 24h postinfusion correlates with the increased Gln/Glu in pgACC at the same time in healthy controls. We assumed the ketamine-induced FC decrease within the DMN reflects the restoration of a connectivity pattern, associated with the antidepressant response. The increases Gln/Glu ratios was found in pgACC, known as a region displaying a deficit in these ratios in subjects with depression. Evidence from this two distinct modulate indicates the linkage between the metabolite change in the core region of DMN and the long-term functional network changes within DMN. Given the limitation of magnetic field strength of human scanner, a further confirmation at high field magnetic strength for rats is desired to investigate Gln/Glu ratio changes in the equivalent brain region with the ability to achieve reliable spectra quantification for Gln. We aim to validate that the relevant RSFC decreases after ketamine administration would mainly be seen in individuals who also show glutamatergic changes in pgACC and/or a relevant BDNF increase. Meanwhile, the FC reconfiguration within DMN and glutamatergic changes in pgACC at Day1 associates with the sustained ketamine response at Day22 in TRD patients. Additionally, Liston and colleagues (8) identified four discrete depression subtypes by distinct patterns of abnormal resting state brain connectivity. The subtype-specific differences further were used to predict individual response to antidepressant therapy. A recent prospective two-site study have confirmed the FC changes at 24 h post ketamine linked to treatment response (19). We aim to apply the same approach as Liston et al. to explore the subtype of TRD patients and further identify which patient subtype would benefit from ketamine administration most. Experiments about validation of neuroimaging markers responding to ketamine in TRD patients and CUMS rats contribute to WP2 (glutamatergic metabolites concentration by MRS and functional connectivity within default mode network by resting state BOLD fMRI in CUMS rats and TRD patients). Experiment with TRD patients will be performed in Tuebingen, while experiment with CUMS rats will be implemented in Mannheim
DFG - Deutsche Forschungsgemeinschaft SA 1869/15-1: Delineating neural circuitry of STress REsilience and Stress Susceptibility using DREADD combined with fMRI technique (STRESS-DREADD). 02/2019-01/2020.
Depression has become the second leading cause of illness-induced disability with 300 million people affected. Suicide due to depression is the second leading cause of death in 15-29-year-olds. Chronic stress exposure greatly raises depression risk. However, there is a degree of inter-individual variation in the way people respond to severe stress, with a spectrum ranging from vulnerability to resilience. Since no current antidepressant is effective for more than 50% of patients, a new frontier in psychiatry could be an induction of natural mechanisms of resilience to treat depression. Our aim is to understand the phenomenon of stress resilience in currently non-explored longitudinal perspective, i.e. to study brain before and after stress in order to separate trait and state-dependent markers of resilience and susceptibility, and also to separate maladaptive from pro-adaptive stress response. The understanding of what makes individuals more resistant to the deleterious effects of stress could suggest new path for the development of treatments. Once we know the key regions and projections discerning resilience and susceptibility, we aim to chemogenetically excite/inhibit these brain projections to find out whether it induces stress resilience in stress-susceptible rats, and vice versa. We will perform a longitudinal study using chronic mild stress model, one of the most realistic and extensively validated animal models of depression, and will use high-field functional magnetic resonance imaging (fMRI) to identify: (1) brain imaging endophenotypes of predisposition to resilience and susceptibility, i.e. trait markers (stress-free environment), (2) state-dependent endophenotypes of resilience and susceptibility (post-stress). Next, we will use a cutting-edge combination of high-field fMRI and a recently developed Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technique, to experimentally probe the effects of focal modulation of key regions and projections discerning resilience and susceptibility, in order to find out whether this manipulation would result in imaging endophenotype and behavior characteristic for stress resilience in stress-susceptible rats, and vice versa. Depression ist die zweithäufigste Ursache für krankheitsbedingte Behinderungen mit ca. 300 Millionen betroffenen Menschen weltweit. Die zweithäufigste Todesursache bei 15-29-Jährigen ist Suizid aufgrund von Depressionen. Eine chronische Belastung durch erhöht das Depressionsrisiko erheblich. Es gibt jedoch ein gewisses Maß an interindividuellen Schwankungen in der Art und Weise, wie Menschen auf schweren Stress reagieren, wobei das Spektrum von Anfälligkeit (Suszeptibilität) bis Belastbarkeit (Resilienz) reicht. Da mehr als 50% der Patienten nicht auf medikamentöse Therapien ansprechen, könnte die Induktion natürlicher Resilienzmechanismen zur Behandlung von Depressionen ein echter therapeutischer Fortschritt in der Psychiatrie sein. Unser Ziel ist es, das Phänomen der Stressresilienz auch longitudinal zu verstehen, d.h. das Gehirn vor und nach Stress zu untersuchen, um merkmals- und zustandsabhängige Marker von Resilienz und Suszeptibilität zu trennen und maladaptive, sowie adaptive Stress-Reaktionen zu erkennen. Das Verständnis dessen, was Individuen gegenüber den schädlichen Auswirkungen von Stress resistenter macht, könnte einen neuen Weg für die Entwicklung von Behandlungen vorschlagen. Sobald wir die Schlüsselregionen und -projektionen kennen, die in Resilienz- und Suszeptibilitätsprozesse involviert sind, wollen wir diese Gehirnprojektionen chemogenetisch anregen / hemmen, um herauszufinden, ob sie Stressresilienz bei Stress-empfindlichen Ratten induzieren und umgekehrt. Geplant ist eine longitudinale Studie mit einem chronisch-milden Stressmodell, welches als Tiermodelle der Depression umfassend validiert ist. Mittels funktioneller Magnetresonanztomographie (fMRT) an einem Hochfeldtomographen wollen wir Folgendes identifizieren: (1) bildgebende Endophänotypen des Gehirns zur Prädisposition Resilienz und Suszeptibilität, d.h. Merkmalsmarker (stressfreie Umgebung), (2) zustandsabhängige Endophänotypen von Resilienz und Suszeptibilität (post-Stress). Als nächstes werden wir eine hochmoderne Kombination aus Hochfeld-fMRT und einer kürzlich entwickelten Designerrezeptoren (DREADD) Technik verwenden, um die Effekte einer fokalen und spezifischen Modulation von Schlüsselregionen und Projektionen, die Stress-Resilienz bzw. -Anfälligkeit abbilden, experimentell zu untersuchen und um herauszufinden, ob diese gezielten Manipulationen zu einem bildgebenden Endophänotyp und Verhaltensänderungen führen, die für Stressresistenz bei Stress - empfindlichen Ratten charakteristisch ist.
Sartorius A. DFG - Deutsche Forschungsgemeinschaft SA 1869/14-1: Designer receptors exclusively activated by designer drugs (DREADDs) used for endophenoptyping neuronal networks of depression by functional connectivity magnetic resonance imaging (fc-fMRI). 07/2017-06/2019.
Depression is a common psychiatric illness affecting up to 17% of the Western population and estimated to be the most prominent cause of disability world-wide by 2020 . About 15% of patients suffering from major depression do not respond to any antidepressant medications or to any other approved procedure. Thus, new treatment options for therapy resistant depression (TRD) are urgently needed. A better understanding of the underlying brain circuits of depression has led to the use of deep brain stimulation (DBS) to treat TRD, but optimal target(s) remain unclear . The monoamine-deficiency hypothesis postulates a deficiency in serotonin or norepinephrine neurotransmission in the brain as a major pathomechanism underlying the disorder. There is, however, a growing body of evidence implicating a role for the glutamatergic system as well [3; 4]. Recently the lateral habenula (LHb) – as a central glutamatergic structure - was reported to mediate depressive-like behavior in rodents, to encode negative motivational value associated with primary punishment in humans and to reveal a new successful target for DBS for patients with therapy-refractory depression [5-9]. Abnormal function of the lateral habenula has been directly linked with major depression [10; 11]. We now aim to express genetically engineered receptors in neuronal cells of the lateral habenula. These receptors can exclusively be activated by a specific designer drug that does not activate endogenous receptors, but will up or downregulate habenula function when the designer drug is applied. Therefore, we will pharmacogenetically upregulate habenula activity to observe both, consecutive changes of depression related neurocircuitries by resting-state functional Magnetic Resonance Imaging (fMRI) [12-14] and concomitant behavioral changes regarding depressive-like behavior [15-17]. This proposed project aims to establish Designer Receptor Exclusively Activated by Designer Drugs (DREADD) of the lateral habenula in rodents as a new experimental treatment strategy. DREADD is a new genetic tool (also called “chemogenetics” or “pharmacogenetics”) to diminish the activity (or to cause burst firing) of genetically defined neurons. For example, the hM4Di-DREADD (a modified Gi-coupled human M4 muscarinic receptor) is activated by the otherwise inert drug-like small molecule clozapine-N-oxide (CNO), resulting in activation of G protein inwardly rectifying potassium channels, hyperpolarizing the cell and attenuating neuronal activity. In contrast, Gq-DREADD = hM3Dq activates another G-Protein cascade and triggers burst firing. In particular, this project would provide to the best of our knowledge the first combination of DREADD with functional connectivity fMRI to identify specifically induced changes of the affected habenular neurocircuitry. Further, for the identification of changes of depression associated neurocircuitry DREADD might be superior to optogenetics-assisted fMRI since it acts more physiological (by receptor activation) and omits imaging artifacts introduced through insertion of fiber optics in the brain for optogenetics . In analogy to the successful implementation of electrical deep brain stimulation in Parkinson's disease (PD) , DREADDing may potentially serve as an alternative future treatment option other than cell replacement therapy for restoring neuronal populations and even deep brain stimulation (DBS) in PD. As a clear and fundamentally new future perspective, DREADD might enable novel treatment strategies of drug resistant depression beyond electric deep brain stimulation, since specific designer drugs have regional and functional specificity and may thus be highly effective with a desirable side effect profile. In other words, we propose a key experiment to show that DREADD could be the future alternative to deep brain stimulation (DBS). Resting state functional connectivity fMRI has been extensively established at our high field animal scanner . After setting up resting state fMRI per se at our 9.4T small animal scanner [21; 22], we did first pharmacological functional connectivity fMRI projects with haloperidol  and ketamine challenges . We performed translational functional connectivity fMRI studies to compare effects with clinical trials  and used graph theory analyses for translational studies as well .
Sartorius A. DFG - Deutsche Forschungsgemeinschaft SA 1869/11-2: "Einfluss von Schilddrüsenhormonen,Schilddrüsenhormonrezeptoren und Schilddrüsenhormontransportern auf Hirnstruktur und -funktion". 09/2015-08/2018.
Thyroid hormones influence brain structure and function not only during development but also have profound effects on cognitive and neural processes in the adult organism in the conditions of hypo- and hyperthyroidism. In the first funding period we used a multimodal imaging battery (voxel-based morphometry, diffusion-tensor-imaging, arterial spin labeling, resting state fMRI, fMRI) and cognitive battery to delinate the effects of hyper- and hypothyroidism. In addition, we have shown that polymorphisms in the thyroid hormone receptor alpha1 gene as well as in the thyroid hormone transporter MCT8 are associated with behavioral effects in the attention and executive function domains. In the second funding period we will apply the established test-battery in two additional cohorts: First, we will examine patients with a mutation in the thyroid hormone beta gene and thyroid hormone resistance to delineate their cognitive and neuronal phenotype. Second, in a new group of normal participants with the polymorphism in the THRA1-gene we will replicate and extend our findings on the cognitive and neuronal phenotype. In addition, we will extend our approach by adding multimodal imaging in transgenic mice (Pax8-/-, Mct8/Oatp1c1 dko) that will be obtained from cooperating projects. Our imaging battery will include resting state fMRI, voxel-based morphometry, and magnetic resonance spectroscopy. The examination of euthyroid, hypothyroid and hyperthyroid Pax8-/- mice will allow the characterization of thyroid hormone effects on brain structure and function in the adult animal similar to our approach in humans. In these animals we will be able to manipulate thyroid hormone levels to a greater extent than in the human, however. Mct8/Oatp1c1 double knock-out mice serve as a model for the human Allan-Herndon-Dudley-Syndrome, and the treatment of these animals with triiodothyroacetic acid or diiodothyropropionic acid will allow us to judge to what extent the effects of the knock-out on brain structure and function are reversible by treatment. Both approaches are complementary and serve our long-term goal to understand the interaction of the thyroid hormone system and the central nervous system.
Schmahl C, Ende G. DFG - Deutsche Forschungsgemeinschaft KFO 256, 2nd funding period: TP 06 Tissue Damage and Pain - Modelling Cutting Behavior in BPD. 08/2015-07/2018.
1 Results of the first funding period To investigate the influence of tissue damage in the context of non-suicidal self-injury (NSSI), we first characterized nociceptive non-invasive stimuli and a mechanical stimulus associated with tissue injury (incision). Twenty healthy men and women each were investigated regarding pain intensity and affective/sensory characteristics of the stimuli. Affective scores were significantly lower than sensory scores for all modalities, including the incision. In women, affective scores were not different for blade, laser and incision stimuli. In a second step, a non-invasive mechanical “blade” stimulus was matched by means of pain intensity with the incision stimulus. Comparing time courses of blade and incision pain, the time course including the pain maximum was very similar (point-by-point comparison between p=0.8 and 1.0). In the ongoing second study, we were successful to induce stress in all groups (current BPD, remitted BPD, healthy controls), verified by significant increase of inner tension and heart rate. An interim analysis of the effects of incision, blade and sham treatment on stress levels in current BPD patients revealed a trend for stronger tension reduction following incision as compared to sham. A similar time course of tension reduction was observed following blade application which appears to be comparably successful to incision in reducing tension. Perception of mechanical pain was lower on both arms in current BPD patients compared to controls, as a sign of generalized hypoalgesia in these patients. Additionally conducted pilot studies investigated the influence of seeing artificial blood together with a pain stimulus on tension reduction and established MR spectroscopy to quantify glutamate and GABA levels in pain-processing brain regions. 2 New questions and work schedule Since the blade stimulus appears to have similar affective pain properties as well as similar influence on tension reduction, it will be used in the studies of the next funding period. The new project has two major objectives. First, we aim to further elucidate mechanisms related to reduced pain sensitivity in BPD using recently established neuroimaging methods. In the second part of the project, we will further disentangle mechanisms related to NSSI with a particular focus on the role of seeing blood and the perspective of the injury (self- vs. other-inflicted) regarding stress reduction. In the first part, we will acquire structural MRIs at 3T and assess morphological group differences in amygdala, anterior cingulate, anterior and posterior insula, and DLPFC as well as volumetric connectivity between these regions in 25 patients with current BPD and 25 healthy controls. Quantitative MRS measures of GABA and glutamate levels will be obtained from the insula and ACC, the glutamate/GABA ratio will be compared between groups, and the association of morphological differences with neurochemical alterations will be investigated. Pseudo-continuous arterial spin labelling (pCASL), which allows absolute quantification of blood flow in pain-processing regions following single stimuli, will be conducted before and after blade stimulation. In the second part, patients with current NSSI will be randomized into four groups of 25 patients each (a) blood, self-inflicted; b)blood, other-inflicted; c) no blood, self-inflicted; d) no blood, other-inflicted). For each patient, an individual stressful script will be prepared and presented while stress levels, and heart rate is 16 monitored. Immediately after the end of the script, the blade stimulus will be applied, either in conjunction with artificial blood or without and either self-inflicted or inflicted by the investigator. The third part is an ambulatory assessment study in which BPD patients carry mobile devices in combination with sensors for physiological signals such as heart rate. Here, we aim to monitor the natural time course of NSSI events in the daily life of BPD patients. Patients will regularly enter their level of subjective stress. In case of NSSI events, stress levels will be prompted more frequently; in addition, painfulness of the NSSI event as well as during the following time period will be closely monitored.
Mann KF, Ende G, Sommer WH. DFG - Deutsche Forschungsgemeinschaft SFB 636: TP D07: Neuroplasticity of brain glutamate and glutamine and treatment. 01/2012-12/2015.
The glutamate hypothesis of alcoholism posits that chronic alcohol intake leads to an enhanced activity of the glutamate system. As soon as alcohol is discontinued, withdrawal develops with marked brain hyperexcitability. Under abstinent conditions this hyperglutamatergic state could be reinstated by stress or alcohol cues and precipitate relapse. Anti-glutamatergic compounds are effective in preventing relapse and potentially also in alleviation of withdrawal. Effect sizes of this pharmacotherapy are moderate, a fact which may be accounted for by individual differences in the extent of neuroplastic changes of the glutamate system. Thus, we predict that antiglutamatergic medications work primarily in individuals who develop a pronounced hyperglutamatergic state, a condition that can be identified and monitored by magnetic resonance spectroscopy (MRS). We previously found that alcohol withdrawal is reflected by increased central glutamate levels. A new measure to be studied in the coming funding period is the glutamate/glutamine ratio which we now can also measure reliably in humans. This ratio will be tested as a potential biomarker for monitoring alcoholism, which may lay the grounds for a personalized treatment approach of this condition. We believe that a translational approach involving human patients and “alcohol dependent rats” serves the purpose of our research best. In both species prefrontal cortex changes in metabolite concentrations during acute withdrawal and into several weeks of abstinence are measured with and without pharmacological interference targeting the glutamatergic system. In the last funding period we developed methods for absolute quantification of metabolites in the human and rat brain. Under control conditions glutamate concentrations in the human anterior cingulate cortex (ACC) and the rat medial prefrontal cortex (mPFC) were highly similar. Thus, for the first time direct evidence for increased central glutamate levels during acute alcohol withdrawal in both species was provided. In the animal experiments, we will induce alcohol dependence through chronic, intermittent, ethanol-vapor exposure. Rats will be assessed repeatedly, over the course of acute alcohol withdrawal into abstinence, for neurometabolic changes in the medial-prefrontal cortex, using MRS at 9.4T. In the new funding period we shall concentrate on the effects of experimental pharmacotherapies for alcohol detoxification (glutamate modulators, such as acamprosate, memantine and lamotrigine) on neurometabolic profiles and on alcohol-related behaviors, comparing these therapies to standard treatments (GABAergic: diazepam). We will also compare neurometabolic profiles to in vivo, microdialysis measurements of extracellular glutamate release from parallel groups of rats. In the human study, we will continue to assess the effects of alcohol withdrawal. As a new element, alcohol cues and pharmacological intervention on levels of glutamate, glutamine and GABA in the prefrontal cortices of treatment-seeking alcoholics will be studied. Alcohol dependent inpatients (n=60) will undergo three combined measurements of MRS and fMRI cue reactivity. The first MR session will take place during acute withdrawal (without medication). The second group of measurements will be taken after five days of abstinence, in order to monitor the glutamate/glutamine ratio over time, and to what extent this ratio is affected by the diazepam that will at this point have been administered for withdrawal-symptom relief. The third MR session will take place on day 14 to monitor the effects of abstinence, both for patients under treatment with acamprosate (which will have been initiated as an open-label treatment following the second MR session) and for patients not being treated with medication. Relapse behavior will be monitored in follow-up assessments, and correlated to MRS metabolites. A control group of n=20 healthy subjects will undergo combined MRS and fMRI twice, two weeks apart.
Schad LR, Ende G. DFG - Deutsche Forschungsgemeinschaft SFB 636: TP Z03: DTI tractography, brain network analysis and advanced translational. 01/2012-12/2015.
As a core project Z03 will give methodological support to those studies within the SFB, that use diffusion tensor imaging (DTI), functional magnetic resonance imaging (fMRI), including real-time fMRI, and magnetic resonance spectroscopy (MRS) at 3.0T as well as advanced imaging and MRS methods at 9.4T. Methods to directly compare functional connectivity and spatiotemporal dynamics acquired with BOLD and regional cerebral blood volume (rCBV)-weighted fMRI in anesthetized rats at the 9.4T scanner will be established. Various MRS editing techniques will be optimized for glutamine, GABA, glutathione, and NAAG detection. Another goal of project Z03 is to combine structural connection maps determined by DTI tractography and/or diffusion spectrum imaging (DSI) with brain network analysis of fMRI data to gain insight into the patterning and dynamics of brain networks and to determine how structural connectivity relates to functional and effective connectivity of the brain. Concepts from graph theory will be used to analyze connection maps and brain network properties. These network properties such as clustering coefficients, characteristic path length or global efficiency can then be quantified and translated to clinical applications.
Sartorius A. BMBF - Bundesministerium für Bildung und Forschung 01GQ1003B: BCCN TP C3: Oscillations and functional connectivity. 05/2010-04/2015.
Ende G, Schmahl C. DFG - Deutsche Forschungsgemeinschaft EN 361/13-1, SCHM 1526/14-1: KFO 256 TP 5: Characteristics and Training of Neural Responding in BPD . 01/2012-12/2014.
Meyer-Lindenberg A. EU - Europäische Union 115008: IMI JU NEWMEDS: Novel Methods Leading to New Medications in Depression and Schizophrenia. 09/2009-08/2014.
Despite remarkable advances in molecular and imaging technologies and nearly 15,000 articles on schizophrenia and depression (S&D) every year, there have been few truly innovative new chemical entities (NCEs) which have made it to the clinic. While there has been a tremendous explosion of new knowledge: dozens of single-nucleotide polymorphisms linked to disease, hundreds of new molecules and pathways identified, numerous imaging findings differentiating patients from controls, yet, it has been hard to take these findings from the bench to the clinic. We think there are three major bottlenecks that are holding the field back: i) a lack of pathophysiologically-accurate animal models guiding the drug discovery of NCEs; ii) a lack of tools and tests in healthy volunteers that can provide early indication of efficacy; and iii) the reliance of clinical trials on symptom-based DSM-categories which inevitably lead to biologically heterogeneous groups of patients. To overcome these limitations, we have brought together a consortium of six leading European and an Israeli academic institution (which bring expertise in animal models, genetics, functional MRI and PET imaging, clinical settings and analysis methods) and two SMEs (which bring expertise in high-throughput genetics, transcriptomics and proteomics) who will partner with the dozen EFPIA partners in the NEWMEDS consortium. To specifically target the challenges identified in Call 10, the NEWMEDS consortium will: a) develop animal models that focus on reliable cross-species endophenotypes (e.g., cognitive function, electrophysiology) and use crossspecies methods (small-animal MRI, EEG and micro-PET) to bring animal models closer to clinical endpoints; b) validate the use of fMRI-based paradigms as early and surrogate markers for efficacy; and to combine this with PET approaches for measuring changes in endogenous transmitters – thus providing new methods that can be implemented in small Phase 1B studies in healthy volunteers to provide guidance for drug development; and c) identify pharmacogenetic biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches – the use of support vector machine learning algorithms for image analyses; the use of Bayesian and growth mixture models for more meaningful analyses of clinical trial data. The project will be delivered through a series of integrated workpackages organized in three clusters – preclinical models, imaging methods, and biomarker development as exemplified in Figure 1. Our consortium has achieved its 1:1 in-kind match, indicative of the involvement and commitment of all EFPIA partners. One of Europe’s leading scientific management SMEs (GABO:mi) will facilitate the management of NEWMEDS and a distinguished international Scientific Advisory Board will provide input and guidance. To ensure that we maximally integrate with other ongoing international initiatives, we have commitments of collaborations from several international consortia and experts (e.g. MATRICS, NIH Biomarkers Consortium). By the end of the 5 year project we expect to provide ready to use new cross-validated animal models, new fMRI methods with dedicated analysis techniques, new PET radioligands, as well as new genetic and proteomic biomarkers for patient-segmentation or individual response prediction. These tools should provide our EFPIA partners with an added competitive advantage in developing new drugs for S&D.
Sartorius A. BMBF - Bundesministerium für Bildung und Forschung 01EW1110: ERA-Net NEURON SuppHab: Improvement of treatment resistant depression by suppression of lateral. 03/2011-02/2014.
About 15% of patients suffering from major depression do not respond to any antidepressant treatment. Recently, deep brain stimulation (DBS) was tested as a new therapeutic approach for these severely ill patients. Here we propose a well controlled study, in an animal model of depression, to test the therapeutic benefits of DBS of the lateral habenula (LHb). We believe that hyperactivity of this structure plays a central role in depression by inhibiting dopaminergic and serotonergic transmission. This hypothesis will be tested by means of magnetic resonance imaging and microdialysis in a well-known animal model of depression and additionally, in depressed patients. Breeding and testing of all animals from the congenital Learned Helpless model will take place in Mannheim and animals will be distributed to partners from here. A subgroup of animals will be investigated by means of cerebral blood volume measurements, functional connectivity analysis and MR-spectroscopy at our 9.4 T scanner. In a final experimental step we will test if helpless behavior can be reversed by DBS and if alterations that have been detected by MR investigation can also be normalised. There is no plan for any business or economic outlook or connectivity. Scientific outlook are excellent publications and improvement and refinement of existing theories of depression. The scientific outlook will be the initiation of a clinical DBS study that takes advantage of the LHb as a new stimulation target to treat therapy refractory depression.
Schmahl C, Ende G. DFG - Deutsche Forschungsgemeinschaft EN 361/12-1, SCHM 1526/13-1: Impulsivität und Stress - behaviorale und MR-spektroskopische Untersuchungen bei der Boderline-Persönlichkeitsstörung und der Aufmerksamheitsdefizit-Hyperaktivitäts-Störung. 09/2011-08/2013.
Impulsivität wird als ein Kernmerkmal vieler psychiatrischer Erkrankungen wie der Borderline-Persönlichkeitsstörung (BPS) und des Aufmerksamkeits-Defizit-Hyperaktivitäts-Syndroms (ADHS) diskutiert. Der Begriff Impulsivität ist jedoch unscharf und umfasst ein komplexes mehrdimensionales Konstrukt. Auf der Verhaltensebene lässt sich Impulsivität als verminderte Reaktionshemmung in Verbindung mit Schwierigkeiten bei der Aufmerksamkeitsfokussierung und einer unsorgfältigen Informationsverarbeitung operationalisieren. Hinzu kommen Schwierigkeiten beim Belohnungsaufschub, stärkere Bevorzugung unmittelbar wirksamer Vermeidungsstrategien auf Kosten langfristig wirksamer Bewältigungsstrategien und reduzierte Handlungskontrolle bei intensivem Ärger und Wut („Impulsive Aggressivität“). Auf neurobiologischer Ebene weisen aktuelle Forschungsbefunde auf eine Beteiligung frontaler Bereiche an der Impulskontrolle sowie auf eine wichtige Rolle des glutamatergen (und evtl. auch des GABAergen) Systems insbesondere im Bereich des anterioren cingulären Kortex hin. Der Zusammenhang zwischen neurochemischen und Verhaltensmaßen ist bislang jedoch noch wenig untersucht. Zudem fehlen bislang noch experimentelle Studien zum Einfluss von Stress auf subjektive und behaviorale Maße der Impulsivität. Das Ziel des geplanten Forschungsprojekts ist es, 1. eine mehrdimensionale Untersuchung von Impulsivität auf Verhaltensebene bei der BPS und ADHS durch den Einsatz mehrerer behavioraler Paradigmen vorzunehmen, 2. diese behavioralen Maße mit neurobiologischen Parametern (Magnetresonanz-Spektroskopie und funktionelle Magnetresonanztomographie) und subjektiven Selbsteinschätzungen (Fragebögen) zu korrelieren, und 3. diese behavioralen Maße in Zusammenhang mit emotionalem Stress zu untersuchen. Dazu sollen 30 Patientinnen mit BPS, 30 Patientinnen mit ADHS und 30 gesunde Probandinnen mit Bildgebung, mehreren psychometrischen Verfahren sowie verschiedenen Verhaltenstests vor und nach einer Stressinduktion untersucht werden.